CY1121815T1 - Αναστολεις αργινασης και μεθοδοι χρησης - Google Patents
Αναστολεις αργινασης και μεθοδοι χρησηςInfo
- Publication number
- CY1121815T1 CY1121815T1 CY20191100747T CY191100747T CY1121815T1 CY 1121815 T1 CY1121815 T1 CY 1121815T1 CY 20191100747 T CY20191100747 T CY 20191100747T CY 191100747 T CY191100747 T CY 191100747T CY 1121815 T1 CY1121815 T1 CY 1121815T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- arginase
- argination
- inhibitors
- chemical formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004452 Arginase Human genes 0.000 abstract 2
- 108700024123 Arginases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 229940080328 Arginase inhibitor Drugs 0.000 abstract 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
Η παρούσα εφεύρεση αφορά ενώσεις αναστολέα αργινάσης του χημικού τύπου ΙΑ ή του χημικού τύπου IB: ΗοΝ, Χi, xi, Η9Ν, X1, χ{xz ^z Χ "x2 ^z R 1 K COOH COOH ΙΑ IB ή ένα φαρμακευτικά αποδεκτό άλας αυτών, συνθέσεις που περιέχουν τις εν λόγω ενώσεις, και μεθόδους χρήσης τους για τη θεραπεία και διάγνωση καταστάσεων που σχετίζονται με την ανοδική ρύθμιση της αργινάσης, με την αφύσικα υψηλή δραστηριότητα αργινάσης, ή με την αφύσικα χαμηλή δραστηριότητα συνθάσης νιτρικού οξειδίου.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14727009P | 2009-01-26 | 2009-01-26 | |
| PCT/US2010/022090 WO2010085797A2 (en) | 2009-01-26 | 2010-01-26 | Arginase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121815T1 true CY1121815T1 (el) | 2020-07-31 |
Family
ID=42354317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100747T CY1121815T1 (el) | 2009-01-26 | 2019-07-12 | Αναστολεις αργινασης και μεθοδοι χρησης |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20100189644A1 (el) |
| EP (1) | EP2389352B1 (el) |
| JP (2) | JP2012515799A (el) |
| CA (1) | CA2749853C (el) |
| CY (1) | CY1121815T1 (el) |
| DK (1) | DK2389352T3 (el) |
| ES (1) | ES2729474T3 (el) |
| HR (1) | HRP20191433T1 (el) |
| HU (1) | HUE046932T2 (el) |
| LT (1) | LT2389352T (el) |
| PL (1) | PL2389352T3 (el) |
| PT (1) | PT2389352T (el) |
| RS (1) | RS58965B1 (el) |
| SI (1) | SI2389352T1 (el) |
| SM (1) | SMT201900320T1 (el) |
| TR (1) | TR201910726T4 (el) |
| WO (1) | WO2010085797A2 (el) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103068830B (zh) * | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| DK2632927T3 (en) * | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| WO2013056163A1 (en) * | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| US10299377B2 (en) | 2011-12-22 | 2019-05-21 | Fujifilm Corporation | Conductive sheet and touch panel |
| CA2870526C (en) | 2012-04-18 | 2020-05-05 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| US9750743B2 (en) * | 2012-12-04 | 2017-09-05 | Aribio Inc. | Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells |
| CA2944903A1 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| KR20180021117A (ko) | 2015-06-23 | 2018-02-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성 억제를 위한 조성물 및 방법 |
| CN108601767A (zh) * | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
| WO2017075363A1 (en) * | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| JP6581308B2 (ja) * | 2016-10-17 | 2019-09-25 | 一般社団法人 金沢大整形 | 癌治療剤 |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| SMT202100573T1 (it) | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| WO2018209290A1 (en) | 2017-05-12 | 2018-11-15 | Calithera Biosciences, Inc. | Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide |
| CN111818928A (zh) | 2018-03-05 | 2020-10-23 | 艾库斯生物科学有限公司 | 精氨酸酶抑制剂 |
| EP3774843B1 (en) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptide piperidine derivatives |
| RU2695333C1 (ru) * | 2018-09-24 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте |
| RU2696580C1 (ru) * | 2018-09-25 | 2019-08-05 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте |
| ES3034676T3 (en) | 2018-11-16 | 2025-08-21 | Arcus Biosciences Inc | Inhibitors of arg1 and/or arg2 |
| CN113395996B (zh) | 2019-02-08 | 2024-05-28 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| CN117417292B (zh) * | 2023-02-20 | 2024-07-12 | 浙江新码生物医药有限公司 | 一种含有杂芳基的非天然氨基酸及其用途 |
| CN117085142A (zh) * | 2023-08-04 | 2023-11-21 | 中山大学附属第七医院(深圳) | 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477391A (en) | 1981-08-14 | 1984-10-16 | Collins James F | Amino acid isomers, their production and their medicinal use |
| WO1999019295A1 (en) * | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| US6784178B2 (en) * | 2000-04-12 | 2004-08-31 | Cornell Research Foundation, Inc. | Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity |
| US20050203082A1 (en) * | 2003-08-13 | 2005-09-15 | Hsu Chung Y. | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
| EP2083812B1 (en) * | 2006-11-21 | 2017-04-05 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
-
2010
- 2010-01-26 SI SI201031897T patent/SI2389352T1/sl unknown
- 2010-01-26 PL PL10734002T patent/PL2389352T3/pl unknown
- 2010-01-26 CA CA2749853A patent/CA2749853C/en not_active Expired - Fee Related
- 2010-01-26 ES ES10734002T patent/ES2729474T3/es active Active
- 2010-01-26 RS RS20190839A patent/RS58965B1/sr unknown
- 2010-01-26 SM SM20190320T patent/SMT201900320T1/it unknown
- 2010-01-26 HR HRP20191433 patent/HRP20191433T1/hr unknown
- 2010-01-26 EP EP10734002.8A patent/EP2389352B1/en active Active
- 2010-01-26 TR TR2019/10726T patent/TR201910726T4/tr unknown
- 2010-01-26 LT LTEP10734002.8T patent/LT2389352T/lt unknown
- 2010-01-26 US US12/693,863 patent/US20100189644A1/en not_active Abandoned
- 2010-01-26 HU HUE10734002A patent/HUE046932T2/hu unknown
- 2010-01-26 JP JP2011548216A patent/JP2012515799A/ja active Pending
- 2010-01-26 PT PT10734002T patent/PT2389352T/pt unknown
- 2010-01-26 DK DK10734002.8T patent/DK2389352T3/da active
- 2010-01-26 WO PCT/US2010/022090 patent/WO2010085797A2/en not_active Ceased
-
2015
- 2015-05-28 JP JP2015108412A patent/JP6177832B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/959,765 patent/US10118936B2/en not_active Expired - Fee Related
-
2018
- 2018-09-28 US US16/145,559 patent/US20190127395A1/en not_active Abandoned
-
2019
- 2019-07-12 CY CY20191100747T patent/CY1121815T1/el unknown
- 2019-08-22 US US16/548,681 patent/US20200223871A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6177832B2 (ja) | 2017-08-09 |
| WO2010085797A2 (en) | 2010-07-29 |
| LT2389352T (lt) | 2019-06-10 |
| JP2015205891A (ja) | 2015-11-19 |
| HUE046932T2 (hu) | 2020-04-28 |
| TR201910726T4 (tr) | 2019-08-21 |
| US20160194340A1 (en) | 2016-07-07 |
| ES2729474T3 (es) | 2019-11-04 |
| AU2010206535A1 (en) | 2011-07-28 |
| PL2389352T3 (pl) | 2019-10-31 |
| US20100189644A1 (en) | 2010-07-29 |
| US20200223871A1 (en) | 2020-07-16 |
| HRP20191433T1 (hr) | 2019-11-15 |
| JP2012515799A (ja) | 2012-07-12 |
| WO2010085797A3 (en) | 2010-11-04 |
| US10118936B2 (en) | 2018-11-06 |
| CA2749853C (en) | 2018-08-21 |
| EP2389352A4 (en) | 2013-02-20 |
| EP2389352A2 (en) | 2011-11-30 |
| US20190127395A1 (en) | 2019-05-02 |
| SI2389352T1 (sl) | 2019-08-30 |
| PT2389352T (pt) | 2019-08-23 |
| SMT201900320T1 (it) | 2019-07-11 |
| RS58965B1 (sr) | 2019-08-30 |
| EP2389352B1 (en) | 2019-05-08 |
| DK2389352T3 (da) | 2019-07-29 |
| CA2749853A1 (en) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121815T1 (el) | Αναστολεις αργινασης και μεθοδοι χρησης | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1118156T1 (el) | Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων | |
| CY1119533T1 (el) | Νεοι θεραπευτικοι παραγοντες | |
| MX377600B (es) | Estimuladores de sgc. | |
| CY1119546T1 (el) | Συνδυαστικη θεραπεια υποκατεστημενης οξαζολιδινονης | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| TR201909189T4 (tr) | C-kit ki̇naz i̇nhi̇bi̇törü bi̇leşi̇kler ve bi̇leşi̇mler | |
| EA201270646A1 (ru) | Ингибиторы глюкозилцерамидсинтазы | |
| BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
| CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
| CY1117424T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| EA201201663A1 (ru) | Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1 | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| CY1118774T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης | |
| UA108240C2 (uk) | Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування | |
| EA201270590A1 (ru) | Ингибиторы акт | |
| EA201071099A1 (ru) | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR | |
| UY33539A (es) | Compuestos químicos alk | |
| CY1123056T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| BR112012019561A2 (pt) | hetarilamino naftiridinas | |
| EA200901473A1 (ru) | Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12 | |
| CY1114735T1 (el) | Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5 |